On August 28, 2023 Virpax Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, reported that it will be presenting virtually at the upcoming H.C. Wainwright event from Monday, September 11th through Wednesday, September 13th starting at 7:00 a.m. ET. Anthony P. Mack, Chairman & CEO of Virpax, will be giving the presentation (Press release, Virpax Pharmaceuticals, AUG 28, 2023, View Source [SID1234634729]). Management will also be hosting in-person and virtual one-on-one meetings during the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: Virpax Presentation at the H.C. Wainwright 25th Annual Global Investment Conference
Date: Monday, September 11th through Wednesday, September 13th
Time: On Demand from 7:00 a.m. ET to 7:00 p.m. ET daily
Webcast: Register Here

A replay of the presentation will also be available for 90 days on the Virpax website.

For more information on the H.C. Wainwright BioConnect Conference or to schedule a one-on-one meeting with Virpax management, please contact your conference representative or you may also email your request to [email protected] or call (917) 923-8541.